ABBV
$271.36+1.75%
as of close, Oct 7, 2026
☾ AH $271.36 +1.75%
ABBV — AbbVie Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDEDEDEDE
60.080.0100.0120.0140.0160.0180.0200.0220.0240.0260.00100.0M$271.36—20162019202120242026
2026-10-07
Price$271.36
MA20$242.10
MA50$228.86
Vol23.4M
Key stats#
Price data
- Price
- $271.36
- YTD price return
- +18.76%
- YTD total return
- +21.57%
- Next earnings
- Oct 30, 2026 · Before open
- Market cap
- 479.5B
- Enterprise value
- 536.4B
- Shares outstanding
- 1.8B
- 52W low
- $190.75
- 52W high
- $274.94
- From 52W high
- -1.30%
- From 52W low
- +42.26%
- 52W range
- 96%
- Beta
- 0.29
Volume
- Rel volume
- 1.27×
- 30D volume
- 4.3M
- 30D $ vol
- 1.1B
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- −$8.2M
- Insider net 1Y
- −$18.9M
Form 4 transactions by trade date, as filed; latest on file 2026-08-14.
Fundamentals
- Sales (ttm)
- 64.4B
- Sales/share
- $36.44
- EPS (ttm)
- $3.54
- FCF (ttm)
- 18.2B
- FCF/share
- $10.30
- Book value/share
- -$3.36
- Net margin
- 9.80%
- ROA
- 4.67%
- Current ratio
- 0.81
Growth (CAGR, ttm) · 10Y
- Sales
- +10.39%+4.75%+3.69%+10.03%
- Net income
- +67.74%-10.10%-1.08%+0.99%
- FCF
- -0.16%-9.78%-1.43%+9.08%
- Shares
- +0.03%+0.04%-0.00%+0.82%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +68.63%-10.02%-0.93%+0.20%
- Sales/share
- +10.36%+4.70%+3.69%+9.14%
- FCF/share
- -0.19%-9.82%-1.43%+8.19%
- Dividend/share
- +5.57%+5.30%+6.44%+11.90%
- Price
- +16.56%+22.30%+19.61%+15.75%
- Total return
- +20.18%+26.59%+24.08%+20.60%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 76.7×
- P/OI (ttm)
- 28.4×
- Fwd P/E
- 16.2×
- P/S (ttm)
- 7.4×
- P/B (mrq)
- -80.8×
- P/FCF (ttm)
- 26.3×
- EV/EBITDA (fy)
- 21.6×
- EV/Sales (ttm)
- 8.3×
- FCF yield (ttm)
- 3.80%
- Dividend yield (fwd)
- 2.55%
- Dividend yield (ttm)
- 2.52%
- Dividend/share (fwd)
- $6.92
- Buyback yield (realized, 1y)
- -0.03%
- Shareholder yield (realized, 1y)
- 3.62%
- Buyback yield (cash, ttm)
- 0.31%
- Shareholder yield (cash, ttm)
- 2.81%
Vs own 10Y history
- P/E
- 87th
- P/OI
- 90th
- P/S
- 100th
- P/B
- 97th
- P/FCF
- 100th
Bar = where today’s multiple sits in ABBV’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-07#
1D
+1.75%
5D
+3.73%
1M
+5.81%
3M
+6.56%
YTD
+18.76%
1Y
+16.55%
5Y
+144.76%
Recent filings#
- Oct 58-K · Results of operations
- Sep 38-K · AbbVie Completes Acquisition of Apogee Therapeutics
- Aug 14Insider sale · Donoghoe Nicholas (EVP, CHIEF BUS/STRAT OFFICER) sold 32,710 shares for $8.2M at $250.00
- Jul 31Earnings · Earnings release — EPS $3.65 vs $3.64 est. (+0.3%); revenue $16.99B (+10% y/y) 2.5%
- Jul 68-K · Results of operations
Financial statements
Open full ABBV financials →Loading financial statements…
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +3.42% | +2.70% |
| JNJ | Johnson & Johnson | -6.10% | +1.44% |
| MRK | Merck & Co. Inc. | -5.02% | +0.60% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -5.33% | -0.09% |
| TMO | Thermo Fisher Scientific Inc. | +7.87% | +0.83% |
| AMGN | Amgen Inc. | -5.52% | +2.60% |
| GILD | Gilead Sciences Inc. | -2.75% | +1.82% |
| ABT | Abbott Laboratories | -8.86% | +0.58% |
